Dashboard
Manage Tickers

DNLI Denali Therapeutics Inc.

Nasdaq denalitherapeutics.com


$ 14.90 $ -0.48 (-3.22 %)    

Thursday, 06-Nov-2025 18:29:44 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 613.00 $ -9.99 (-1.61 %)
DIA $ 470.27 $ -2.78 (-0.59 %)
SPY $ 671.69 $ -6.30 (-0.93 %)
TLT $ 89.67 $ 0.21 (0.23 %)
GLD $ 366.64 $ -1.11 (-0.3 %)
$ 14.41
$ 14.96
$ 14.75 x 5
$ 15.87 x 215
$ 14.30 - $ 15.10
$ 10.57 - $ 33.33
1,180,759
na
2.11B
$ 1.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-04-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-26-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-07-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-12-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 03-19-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

denali-therapeutics-q3-eps-074-beats-075-estimate
Denali Therapeutics Q3 EPS $(0.74) Beats $...
11/06/2025 21:58:54

jp-morgan-maintains-overweight-on-denali-therapeutics-raises-price-target-to-26
JP Morgan Maintains Overweight on Denali T...
11/04/2025 15:00:58

JP Morgan analyst Jessica Fye maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from...

fda-delays-decision-date-for-denali-therapeutics-lead-drug-candidate
FDA Delays Decision Date For Denali Therap...
10/14/2025 18:43:36

FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident i...

denali-therapeutics-announces-fda-extends-the-review-timeline-for-its-biologics-license-application-for-tividenofusp-alfa-a-potential-treatment-for-hunter-syndrome
Denali Therapeutics Announces FDA Extends ...
10/13/2025 20:03:25

Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review...

cantor-fitzgerald-reiterates-overweight-on-denali-therapeuticsto-overweight
Cantor Fitzgerald Reiterates Overweight on...
09/08/2025 13:20:05

Cantor Fitzgerald analyst Josh Schimmer reiterates Denali Therapeutics (NASDAQ:DNLI) from Overweight to Overweight.

morgan-stanley-maintains-overweight-on-denali-therapeutics-lowers-price-target-to-30
Morgan Stanley Maintains Overweight on Den...
08/18/2025 13:17:23

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price t...

denali-therapeutics-q2-eps-072-misses-062-estimate
Denali Therapeutics Q2 EPS $(0.72) Misses ...
08/11/2025 20:19:42

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of...

denali-therapeutics-announces-fda-acceptance-priority-review-of-biologics-license-application-for-tividenofusp-alfa-for-hunter-syndrome-sets-pdufa-date-of-jan-5-2026
Denali Therapeutics Announces FDA Acceptan...
07/07/2025 12:03:08

FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approvalTividenofusp alfa is designed to d...

b-of-a-securities-maintains-buy-on-denali-therapeutics-lowers-price-target-to-27
B of A Securities Maintains Buy on Denali ...
05/19/2025 17:56:44

B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target fr...

Core News & Articles
'FDA Clears First Blood Test Used In Diagn...
05/16/2025 17:32:57

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%...

baird-maintains-outperform-on-denali-therapeutics-lowers-price-target-to-29
Baird Maintains Outperform on Denali Thera...
05/08/2025 12:42:18

Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $30...

wedbush-maintains-outperform-on-denali-therapeutics-lowers-price-target-to-30
Wedbush Maintains Outperform on Denali The...
05/07/2025 16:02:32

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $...

hc-wainwright--co-maintains-buy-on-denali-therapeutics-lowers-price-target-to-32
HC Wainwright & Co. Maintains Buy on Denal...
05/07/2025 13:38:10

HC Wainwright & Co. analyst Andrew Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price targ...

denali-therapeutics-q1-eps-078-misses-068-estimate
Denali Therapeutics Q1 EPS $(0.78) Misses ...
05/06/2025 20:49:36

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of...

what-happened-to-denali-therapeutics-stock-wednesday
What Happened To Denali Therapeutics Stock...
04/02/2025 20:10:55

Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license app...

denali-therapeutics-initiates-bla-filing-ror-accelerated-approval-of-tividenofusp-alfa-for-treatment-of-hunter-syndrome-and-positive-ongoing-interactions-with-fda-on-dnl126-through-start-program
Denali Therapeutics Initiates BLA Filing R...
04/02/2025 12:09:10

Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 20...

b-of-a-securities-maintains-buy-on-denali-therapeutics-lowers-price-target-to-28
B of A Securities Maintains Buy on Denali ...
03/10/2025 16:52:03

B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target fr...

morgan-stanley-assumes-denali-therapeutics-at-overweight-lowers-price-target-of-33
Morgan Stanley Assumes Denali Therapeutics...
03/07/2025 17:23:30

Morgan Stanley analyst Matthew Harrison assumes Denali Therapeutics (NASDAQ:DNLI) with a Overweight rating and lowers Price ...

denali-therapeutics-ends-als-trial-extension-analyst-stays-optimistic-despite-trial-setback
Denali Therapeutics Ends ALS Trial Extensi...
03/06/2025 17:06:29

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analys...

on-wednesday-denali-therapeutics-discontinued-the-active-treatment-extension-in-regimen-g-of-the-phase-23-healey-als-platform-trial-of-eif2b-agonist-dnl343-for-amyotrophic-lateral-sclerosis-8k
On Wednesday, Denali Therapeutics Disconti...
03/06/2025 10:02:23

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION